News Release

Anti-obesity medication tirzepatide remains effective even for those with diabetes and other complications

Reports and Proceedings

The Endocrine Society

BOSTON—Having medical conditions linked to obesity does not impact the total weight loss achieved with the anti-obesity medication tirzepatide, according to an industry-supported study being presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass. 

Obesity causes or worsens over 200 diseases. It has been widely believed that when patients suffer multiple medical problems, they are not able to lose as much weight as those without medical issues. The new study, funded by tirzepatide maker Eli Lilly Inc., was designed to see if having more obesity-associated diseases results in less weight loss.

“Overall, tirzepatide treatment resulted in significant weight loss, regardless of the number of obesity-related complications patients had at the outset of the study,” said lead researcher Sriram Machineni, M.D., of the Albert Einstein College of Medicine/Montefiore Medical Center in the Bronx, N.Y.

Tirzepatide, a once-weekly GLP-1 receptor agonist, was approved in November 2023 by the U.S. Food and Drug Administration under the trade name Zepbound for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes or high cholesterol). Tirzepatide was previously approved by the FDA under the trade name Mounjaro to treat type 2 diabetes.

The researchers combined the results from four different trials. The designs of each study and the patient characteristics were different, but all the patients had obesity. There were a total of 4,726 subjects, all of whom either had obesity (a body mass index, or BMI, of greater than 30), or overweight (a BMI of at least 27) along with an obesity-related medical condition. A subset of 938 subjects from one of the four trials had type 2 diabetes.

The weight losses achieved in the tirzepatide groups were classified by the number of obesity-related conditions (no other medical conditions, one such condition, or two or more) compared to patients who received a placebo.

Participants who were older or had obesity for longer had a greater number of obesity-related comorbidities, as would be expected. Greater reductions in body weight were seen in participants treated with tirzepatide compared with placebo, regardless of the presence of other obesity-related conditions.

# # #

Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions. 

The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at Follow us on Twitter at @TheEndoSociety and @EndoMedia.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.